Solution structure of the anti-apoptotic protein Bcl-xL in complex with an acyl-sulfonamide-based ligand

Experimental Data Snapshot

  • Method: SOLUTION NMR
  • Conformers Submitted: 

wwPDB Validation   3D Report Full Report

This is version 2.1 of the entry. See complete history


An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Oltersdorf, T.Elmore, S.W.Shoemaker, A.R.Armstrong, R.C.Augeri, D.J.Belli, B.A.Bruncko, M.Deckwerth, T.L.Dinges, J.Hajduk, P.J.Joseph, M.K.Kitada, S.Korsmeyer, S.J.Kunzer, A.R.Letai, A.Li, C.Mitten, M.J.Nettesheim, D.G.Ng, S.Nimmer, P.M.O'Connor, J.M.Oleksijew, A.Petros, A.M.Reed, J.C.Shen, W.Tahir, S.K.Thompson, C.B.Tomaselli, K.J.Wang, B.Wendt, M.D.Zhang, H.Fesik, S.W.Rosenberg, S.H.

(2005) Nature 435: 677-681

  • DOI: https://doi.org/10.1038/nature03579
  • Primary Citation of Related Structures:  
    1YSG, 1YSI, 1YSN, 1YSW, 1YSX

  • PubMed Abstract: 

    Proteins in the Bcl-2 family are central regulators of programmed cell death, and members that inhibit apoptosis, such as Bcl-X(L) and Bcl-2, are overexpressed in many cancers and contribute to tumour initiation, progression and resistance to therapy. Bcl-X(L) expression correlates with chemo-resistance of tumour cell lines, and reductions in Bcl-2 increase sensitivity to anticancer drugs and enhance in vivo survival. The development of inhibitors of these proteins as potential anti-cancer therapeutics has been previously explored, but obtaining potent small-molecule inhibitors has proved difficult owing to the necessity of targeting a protein-protein interaction. Here, using nuclear magnetic resonance (NMR)-based screening, parallel synthesis and structure-based design, we have discovered ABT-737, a small-molecule inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w, with an affinity two to three orders of magnitude more potent than previously reported compounds. Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation. ABT-737 exhibits single-agent-mechanism-based killing of cells from lymphoma and small-cell lung carcinoma lines, as well as primary patient-derived cells, and in animal models, ABT-737 improves survival, causes regression of established tumours, and produces cures in a high percentage of the mice.

  • Organizational Affiliation

    Idun Pharmaceuticals, 9380 Judicial Drive, San Diego, California 92121, USA.

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Apoptosis regulator Bcl-X181Homo sapiensMutation(s): 0 
UniProt & NIH Common Fund Data Resources
Find proteins for Q07817 (Homo sapiens)
Explore Q07817 
Go to UniProtKB:  Q07817
PHAROS:  Q07817
GTEx:  ENSG00000171552 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ07817
Sequence Annotations
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
Query on N3B

Download Ideal Coordinates CCD File 
C27 H22 F N3 O5 S2
Binding Affinity Annotations 
IDSourceBinding Affinity
N3B PDBBind:  1YSI Ki: 36 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: SOLUTION NMR
  • Conformers Submitted: 

Structure Validation

View Full Validation Report

Entry History 

Revision History  (Full details and data files)

  • Version 1.0: 2005-06-07
    Type: Initial release
  • Version 1.1: 2007-10-17
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Version format compliance
  • Version 2.0: 2022-03-02
    Changes: Atomic model, Database references, Derived calculations
  • Version 2.1: 2024-05-22
    Changes: Data collection